Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 11 Oct 2021
Review of the National Medicines Policy
11 October 2021 - The call for submissions closed on Friday 8 October 2021 and a total of 107 submissions have ...
Posted by Michael Wonder on 10 Oct 2021
PHARMAC negotiates deal for molnupiravir to treat COVID-19
11 October 2021 - PHARMAC has negotiated an agreement with supplier MSD to purchase the antiviral molnupiravir. ...
Posted by Michael Wonder on 10 Oct 2021
70 percent of Kiwis want Government to give PHARMAC more money - survey
10 October 2021 - New Zealanders have sent a clear message to the Government to fund medicines better or their ...
Posted by Michael Wonder on 10 Oct 2021
Brii Bio initiates submission of emergency use authorisation filing to U.S. FDA for BRII-196/BRII-198, its monoclonal antibody combination therapy for non-hospitalised COVID-19 patients at high risk of clinical progression to severe disease
8 October 2021 - Data supporting the EUA filing will be submitted to the FDA on a rolling basis with the ...
Posted by Michael Wonder on 10 Oct 2021
New FDA chief can't come soon enough for beleaguered agency
8 October 2021 - One of the leading agencies in the government’s fight against COVID-19 is finally on the verge of ...
Posted by Michael Wonder on 09 Oct 2021
Alpha Tau receives FDA's breakthrough device designation for the treatment of recurrent glioblastoma multiforme
8 October 2021 - Alpha Tau Medical is pleased to announce that it has received breakthrough device designation for Alpha ...
Posted by Michael Wonder on 09 Oct 2021
Egetis Therapeutics receives FDA fast track designation for Emcitate for MCT8 deficiency
8 October 2021 - Egetis Therapeutics today announced that the U.S. FDA has granted the company’s lead candidate drug Emcitate, currently ...
Posted by Michael Wonder on 09 Oct 2021
FDA approves innovative treatment for paediatric patients with congenital athymia
8 October 2021 - Today, the U.S. FDA approved Rethymic for the treatment of paediatric patients with congenital athymia, a rare ...
Posted by Michael Wonder on 08 Oct 2021
Janssen submits application seeking U.S. FDA approval of Stelara (ustekinumab) for the treatment of paediatric patients with juvenile psoriatic arthritis
8 October 2021 - Application utilises extrapolation-based strategy across existing breadth of Stelara data in patients living with this chronic inflammatory ...
Posted by Michael Wonder on 08 Oct 2021
Genentech’s anti-amyloid beta antibody gantenerumab granted FDA breakthrough therapy designation in Alzheimer’s disease
8 October 2021 - Gantenerumab is an investigational antibody in Phase 3 development for early Alzheimer's disease. ...
Posted by Michael Wonder on 08 Oct 2021
ChemoCentryx announces FDA approval of Tavneos (avacopan) in ANCA associated vasculitis
8 October 2021 - First FDA approved orally administered inhibitor of the complement 5a receptor. ...
Posted by Michael Wonder on 08 Oct 2021
Docs ‘use rubber stamp for drugs’
9 October 2021 - Pharmacists have raised the alarm over the influence of a US pharmaceutical corporation on Australian doctors ...
Posted by Michael Wonder on 08 Oct 2021
Booster shot for severely immunocompromised Australians
8 October 2021 - From next week Australians who are severely immunocompromised will be offered the option to receive a third ...
Posted by Michael Wonder on 08 Oct 2021
Recursion is granted FDA fast track designation for REC-2282 for the potential treatment of NF2 mutated meningiomas
7 October 2021 - Recursion today announced that the U.S. FDA has granted the company fast track designation for the ...
Posted by Michael Wonder on 08 Oct 2021
Health Canada approves the use of Rinvoq (upadacitinib) for the treatment of adults and adolescents with moderate to severe atopic dermatitis
7 October 2021 - Authorization is based on the results from three Phase 3 multicenter, randomized, double-blind, placebo-controlled registrational clinical trials ...